Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular Carcinoma
NCT07179900Phase 2Recruiting
- Sponsor
- The Fourth Hospital of Hebei Medical University
- Start
- Mar 2025
- Primary completion
- Dec 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of QL1706 in hepatocellular carcinoma (HCC), sponsored by The Fourth Hospital of Hebei Medical University. Started Mar 2025; status: recruiting.
02
Drugs
QL1706
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07179900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07179900.